Amgen (AMGN) Stock Dips While Market Gains: Key Facts
π Amgen shares dipped 3.38% to close at $407.27, underperforming the broader market and lagging the Medical sector.
π Analysts project quarterly EPS of $5.69 (up 0.89%) and revenue of $9.91 billion (up 3.68%) for the upcoming earnings report.
π Full-year consensus estimates indicate EPS of $22.94 and revenue of $38.81 billion, reflecting roughly 5% growth from the previous year.
π° Amgen trades at a Forward P/E ratio of 18.38, offering a discount compared to the industry average of 22.46.
π The company's PEG ratio is 3.04, which is notably higher than the industry average of 1.91.
π Amgen currently holds a Zacks Rank of #3 (Hold), with consensus EPS estimates having moved 0.15% lower in the past month.
Bullish Signals
- The company trades at a Forward P/E ratio of 18.38, which represents a discount compared to its industry average of 22.46.
- Analysts project quarterly revenue growth of 3.68% to $9.91 billion and full-year earnings growth of approximately 5%.
Risk Factors
- Shares fell 3.38% in the latest session, underperforming both the S&P 500 and the Medical sector.
- The company's PEG ratio of 3.04 is significantly higher than the industry average of 1.91, suggesting a potentially expensive valuation relative to growth.
- Consensus EPS estimates have moved 0.15% lower within the past month, reflecting slight downward pressure on near-term expectations.
Full Analysis
Amgen (AMGN) shares closed at $407.27, marking a 3.38% decline despite broader market gains in the S&P 500 and Nasdaq. The stock underperformed the Medical sector, which also saw losses prior to today's session. This dip occurred while analysts and investors await the company's upcoming earnings disclosure.
Analysts project Amgen's quarterly earnings per share (EPS) at $5.69, representing a 0.89% increase year-over-year, with revenue estimated at $9.91 billion, up 3.68%. Full-year consensus estimates forecast EPS of $22.94 and revenue of $38.81 billion, indicating projected growth of approximately 5% for both metrics compared to the prior year.
Valuation metrics show Amgen trading at a Forward P/E ratio of 18.38, which is below the industry average of 22.46. However, the company's PEG ratio stands at 3.04, significantly higher than the Medical - Biomedical and Genetics industry average of 1.91. The stock currently holds a Zacks Rank of #3 (Hold), with recent consensus EPS estimates moving slightly lower.